RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q4 2022
Top Holdings70 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 7M | $849.7M | 17.2% | $95.96 | +27.27% | 17 qtrssince 2018-Q4 | Decreased 0 |
VAXCYTE INC | 5.9M | $280.9M | 5.7% | $33.74 | +42.13% | 11 qtrssince 2020-Q2 | Increased 75 |
| 8.3M | $242.1M | 4.9% | — | — | 7 qtrssince 2021-Q2 | Unchanged 0 | |
DICE THERAPEUTICS INC | 6.8M | $213.7M | 4.3% | — | — | 6 qtrssince 2021-Q3 | Increased 71 |
VERONA PHARMA PLC | 6.3M | $165.1M | 3.3% | — | — | 10 qtrssince 2020-Q3 | Increased 58 |
RHYTHM PHARMACEUTICALS INC | 5.5M | $160.6M | 3.3% | $23.47 | +24.05% | 17 qtrssince 2018-Q4 | Increased 56 |
DAY ONE BIOPHARMACEUTICALS I | 7M | $151.5M | 3.1% | $19.64 | +9.59% | 7 qtrssince 2021-Q2 | Unchanged 0 |
Vor Biopharma Inc. | 22.7M | $151.3M | 3.1% | — | — | — | — |
BIOGEN IDEC INC | 532,892 | $147.6M | 3.0% | $222.99 | +24.19% | 4 qtrssince 2022-Q1 | Decreased 0 |
CYTEK BIOSCIENCES INC | 13.4M | $136.6M | 2.8% | $18.15 | -43.74% | 6 qtrssince 2021-Q3 | Unchanged 0 |
Legend Biotech Corp. Sponsored ADR | 2.4M | $121.6M | 2.5% | $40.50 | +23.25% | 2 qtrssince 2022-Q3 | Increased 54 |
| 5.5M | $121M | 2.5% | $20.94 | +5.97% | 6 qtrssince 2021-Q3 | Increased 83 | |
WAVE LIFE SCIENCES LTD | 17.2M | $120.4M | 2.4% | $20.65 | -66.10% | 17 qtrssince 2018-Q4 | Unchanged 0 |
JANUX THERAPEUTICS INC | 8.7M | $114.2M | 2.3% | $25.37 | -48.09% | 7 qtrssince 2021-Q2 | Unchanged 0 |
89BIO INC | 9M | $114M | 2.3% | — | — | 13 qtrssince 2019-Q4 | Increased 59 |
PEPGEN INC | 8.1M | $108.7M | 2.2% | $10.40 | +28.56% | 3 qtrssince 2022-Q2 | Unchanged 0 |
IMMUNOGEN INC | 21.9M | $108.4M | 2.2% | — | — | 10 qtrssince 2020-Q3 | Increased 52 |
BELLUS HEALTH INC NEW | 12.5M | $102.4M | 2.1% | — | — | 5 qtrssince 2021-Q4 | Increased 56 |
Inhibrx Biosciences, Inc. | 3.9M | $95M | 1.9% | — | — | 1 qtr | New 68 |
Celldex Therapeutics, Inc. | 2.1M | $92.5M | 1.9% | $48.42 | -7.95% | 6 qtrssince 2021-Q3 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $4.9B across 70 positions as of Q4 2022. Top holdings: ASND (17.2%), PCVX (5.7%), AEROVATE THERAPEUTICS INC (4.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 10 new positions, 21 exits, 17 increased. Top move: RNAM (INCREASED, conviction 83). Portfolio: $4.9B across 70 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer